Search
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalTifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
KER-047
go.drugbank.com/drugs/DB19111InvestigationalKER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (
Synonyms: QUINOLINE, 7-FLUORO-6-METHOXY-4-(6-(4-(4-METHYL-1-PIPERAZINYL)-1-PIPERIDINYL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-Fexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalFood and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigationaldue to a decreased tendency of gadolinium dechelation. … Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA).
Categories: Compounds used in a research, industrial, or household settingZidebactam
go.drugbank.com/drugs/DB13090ApprovedZidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalA full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … The FDA said it is keeping the black box in place at least until the results of the trial are announced.
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalThe FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexHuman botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Synonyms: Human botulinum neurotoxin A/B immune globulin